Want to see SE:ISOFOL full AI Analyst Report?
Top Page
Isofol Medical AB
(ISOFOL)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr0.79
▲(10.28% Upside)
Action:Reiterated
Date:08/27/26
The score is held back primarily by weak financial performance (minimal revenue, ongoing losses, and cash burn), only partly offset by a low-debt balance sheet. Technicals are neutral-to-mildly supportive longer term, while valuation remains constrained by negative earnings and no indicated dividend yield.
Positive Factors
No Financial Debt
A debt-free balance sheet limits interest obligations and refinancing risk, giving Isofol greater flexibility to direct available capital toward oncology development and regulatory activities.
Negative Factors
No Meaningful Revenue
The absence of recurring product revenue confirms that Isofol remains pre-commercial, leaving future value dependent on clinical success, regulatory approval and eventual commercialization or partnering.
Read all positive and negative factors
Positive Factors
Negative Factors
No Financial Debt
A debt-free balance sheet limits interest obligations and refinancing risk, giving Isofol greater flexibility to direct available capital toward oncology development and regulatory activities.
Read all positive factors
Isofol Medical AB (ISOFOL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr241.33M
Dividend YieldN/A
Average Volume (3M)502.50K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue GrowthN/A
EPS Growth32.79%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding320,491,640
10 Day Avg. Volume592,348
30 Day Avg. Volume502,501
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Isofol Medical AB Business Overview & Revenue Model
Company Description
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is ...
How the Company Makes Money
As a clinical-stage biotechnology company, Isofol Medical AB has historically not generated recurring revenue from product sales (no approved commercial products). Its funding has therefore primarily come from external financing rather than operat...
Isofol Medical AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 721.00K | 12.80M | 22.41M |
| Gross Profit | 0.00 | 0.00 | -38.73M | -34.41M | -165.71M | -174.31M |
| EBITDA | -58.60M | -54.76M | -47.21M | -37.02M | -159.73M | -198.49M |
| Net Income | -56.63M | -54.17M | -43.49M | -37.07M | -159.79M | -200.25M |
Balance Sheet | ||||||
| Total Assets | 118.56M | 129.40M | 98.42M | 140.60M | 213.46M | 401.36M |
| Cash, Cash Equivalents and Short-Term Investments | 114.83M | 126.99M | 96.16M | 138.15M | 190.58M | 379.45M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 3.95M | 1.65M |
| Total Liabilities | 23.55M | 21.52M | 20.47M | 19.16M | 54.99M | 83.13M |
| Stockholders Equity | 95.01M | 107.87M | 77.94M | 121.43M | 158.48M | 318.23M |
Cash Flow | ||||||
| Free Cash Flow | -700.00K | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Operating Cash Flow | -52.63M | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 101.00K | 0.00 | 0.00 |
| Financing Cash Flow | 101.96M | 84.07M | 0.00 | 0.00 | 23.00K | 450.48M |
Isofol Medical AB Technical Analysis
Negative
0.72
Price Trends
0.80
Negative
0.75
Positive
0.72
Positive
Market Momentum
-0.01
Positive
39.96
Neutral
20.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.80, and above the 200-day MA of 0.72, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.96 is Neutral, neither overbought nor oversold. The STOCH value of 20.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ISOFOL.
Isofol Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr497.63M | 2.60 | 63.09% | ― | ― | ― | |
53 Neutral | kr678.44M | -2.28 | ― | ― | 87.23% | 35.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr241.33M | -3.70 | -54.41% | ― | ― | 32.79% | |
48 Neutral | kr192.20M | -8.14 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr466.87M | -4.11 | -18.05% | ― | ― | 15.97% | |
43 Neutral | kr1.60B | -3.22 | -99.58% | ― | -87.22% | -70.29% |
* Healthcare Sector Average
SE:ISOFOL
Isofol Medical AB
0.75
-0.10
-11.41%
SE:BINV
BioInvent International AB
24.30
-5.10
-17.35%
SE:ONCO
Oncopeptides AB
1.78
-3.17
-64.06%
SE:ELIC
Elicera Therapeutics AB
2.88
-3.78
-56.78%
SE:IMMU
Immunicum AB
7.36
0.46
6.67%
SE:CANTA
Cantargia AB
1.77
-0.83
-31.85%
Isofol Medical AB Corporate Events
Isofol Deepens Arfolitixorin Push as Cash Reserves Bolster Pre-Revenue Pipeline
Aug 25, 2026
Isofol Medical AB reported its interim results for January to June 2026, highlighting a continued strategic focus on clinical development rather than commercial revenues. The company remains pre-revenue, posting a first-half loss of kSEK -30,790, ...
Isofol expands arfolitixorin cancer trial to accelerate patient recruitment
Aug 24, 2026
Isofol Medical is expanding its phase Ib/II clinical study of arfolitixorin in colorectal cancer by adding new trial sites, including Essen University Hospital in Germany, to accelerate patient recruitment. The move follows regulatory approval of ...
Isofol advances arfolitixorin trial with final dose cohort in colorectal cancer study
Jul 8, 2026
Isofol Medical AB has advanced its phase Ib/II clinical trial of arfolitixorin, announcing completion of the third dose level in metastatic colorectal cancer patients without dose-limiting toxicities. Following a favorable safety review, the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.